Companies: 10,795·Total market cap: $144.5T
BriaCell Therapeutics Corp. Warrant

BriaCell Therapeutics Corp. Warrant

BCTXZNASDAQHealthcare● Active
$0.08
+$0.00(+0.75%)
Market Cap$150888
P/E Ratio—
52W High$0.0863
52W Low$0.065
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

BriaCell Therapeutics Corp. Warrant (BCTXZ) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001610820 · BCTXZ · NASDAQ · as of Jun 8, 2026

Filing snapshot

321
Total Filings
8-K
Latest Form
2026-06-03
Most Recent
2025
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001610820 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2025-10-16
Fiscal Year End
Oct 16, 2025
Accession No.
0001493152-25-018212
Primary Document
form10-k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001610820 · Accession 0001493152-25-018212

Latest Key Filings

6-KQuarterly Report
Quarterly Report
2022-07-18
View 6-K on SEC
8-KCurrent Report
8-K
2026-06-03Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-03
View
424B5424B5
424B5
2026-06-02
View
8-KCurrent Report
8-K
2026-03-31
View
10-QQuarterly Report
10-Q
2026-03-10
View
8-KCurrent Report
8-K
2026-03-09
View
25-NSE25-NSE
25-NSE
2026-02-26
View
8-KCurrent Report
8-K
2026-02-20
View
DEF 14AProxy Statement
DEF 14A
2026-02-12
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-01-23
View
8-KCurrent Report
8-K
2026-01-15
View
424B4424B4
424B4
2026-01-14
View
EFFECTEFFECT
EFFECT
2026-01-13
View
S-1MEFS-1MEF
S-1MEF
2026-01-13
View
CERTCERT
CERT
2026-01-13
View
8-A12B8-A12B
8-A12B
2026-01-13
View
Showing 1–15 of 317 filingsForm 4 / 144 hidden· 321 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001610820  |  Exchange: NASDAQ · Healthcare

BriaCell Therapeutics Corp. Warrant (NASDAQ: BCTXZ) has submitted 321 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2025. As a Healthcare sector company with CIK 0001610820, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is BriaCell Therapeutics Corp. Warrant's most comprehensive regulatory disclosure. The most recent BriaCell Therapeutics Corp. Warrant 10-K was filed on 2025-10-16 for fiscal year ending 2025. Historical BCTXZ 10-K annual reports are available from 2014 through 2025.

Investors researching BriaCell Therapeutics Corp. Warrant SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
AIMD SEC Filings →NKGN SEC Filings →MLEC SEC Filings →ELAB SEC Filings →NCEL SEC Filings →ATXI SEC Filings →VRAX SEC Filings →DRMA SEC Filings →
→ BCTXZ Financials→ BCTXZ Earnings→ BCTXZ Insider Trades

Frequently Asked Questions

BCTXZ SEC Filings · 8 questions

BriaCell Therapeutics Corp. Warrant (BCTXZ) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 321 filings and access original documents at no cost. BriaCell Therapeutics Corp. Warrant's CIK is 0001610820.

BCTXZ SEC filingsBriaCell Therapeutics Corp. Warrant SEC documentsfind BCTXZ 10-K